Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage TechBio company that regularly issues news and updates about its platform, pipeline and partnerships. As a biotechnology company focused on decoding biology to radically improve lives, Recursion generates announcements that span clinical trial readouts, business development milestones and technology advances related to its Recursion OS.
News for RXRX often highlights progress in clinical programs, such as the TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP), the ELUCIDATE Phase 1/2 trial of REC-617 in advanced solid tumors and ovarian cancer, and the DAHLIA Phase 1/2 study of REC-1245 in solid tumors. Company communications describe efficacy, safety, and design details for these studies, as well as plans for future data readouts and regulatory interactions.
Investors also see frequent updates on partnerships and collaborations. Recursion reports milestones from its long-term collaboration with Genentech and F. Hoffmann-La Roche Ltd, including acceptance of whole-genome phenotypic maps such as a microglia map, and from its multi-target collaboration with Sanofi in oncology and immunology. These items often include information about milestone payments and the scope of ongoing discovery work.
Additional RXRX news covers financial results and capital markets activity, such as quarterly earnings releases, cash runway commentary, and disclosures related to registration statements and share issuances connected to collaborations or acquisitions. The company also announces participation in healthcare and investor conferences, webinars on clinical data, and leadership changes, including CEO transition plans.
By following the RXRX news feed, readers can track how Recursion’s Recursion OS platform is being applied across its internal pipeline and partnered programs, as well as how business decisions, collaborations and governance developments may shape the company’s trajectory in the TechBio and biotechnology sectors.
Recursion (NASDAQ: RXRX) updated its clinical trial guidance, including a significant delay for a Phase 2 trial of REC-3599 in Tay-Sachs disease, now expected to start in approximately two years. However, the company is on track for several other trials: REC-994 for Cerebral Cavernous Malformation, REC-2282 for Neurofibromatosis Type 2, and REC-4881 for Familial Adenomatous Polyposis, with expected patient enrollment in Q2 2022. Preparations for a Phase 1 study of REC-3964 in recurrent C. difficile colitis are also proceeding as planned, aiming for enrollment in the second half of 2022.
Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its participation in two major investor conferences:
- KeyBanc Capital Markets Emerging Technology Summit — March 8-9, 2022
- SVB Leerink Mountain Meeting — March 20-23, 2022
Webcasts will be accessible via the investor section on their website. Recursion utilizes advanced technologies to enhance drug discovery, boasting one of the largest biological datasets and powerful computational resources, aiming to revolutionize medicine.
Recursion (NASDAQ: RXRX) has announced its participation in the upcoming SVB Leerink 11th Annual Global Healthcare Conference from February 14 to February 18, 2022. The conference will feature webcasts accessible in the investor section of www.Recursion.com.
Recursion is a clinical-stage biotechnology firm that focuses on industrializing drug discovery by decoding biology, leveraging its extensive datasets and advanced machine-learning algorithms.
Recursion (NASDAQ: RXRX) announced an expanded collaboration with Bayer AG focusing on fibrosis. The partnership will leverage Recursion's inferential search capabilities to accelerate drug discovery and development in fibrotic diseases, increasing the total number of relevant programs to over a dozen. Each program could yield more than $100 million in milestone payments plus royalties. This collaboration builds on successful prior efforts, with Recursion aiming to operationalize drug discovery more efficiently.
Recursion (NASDAQ: RXRX) announced the appointment of three experts to strengthen its neuroscience focus: Tim Ahfeldt as Fellow, Neuroscience; Irit Rappley as VP, Neuroscience and Translational Research; and Glenn Morrison as VP, Clinical Development. These hires aim to enhance the industrialization of iPSC-derived neural cell types, advance CNS-targeted therapeutics, and propel existing programs through clinical development. The move addresses significant unmet needs in brain disease therapies, leveraging machine learning for novel drug discovery.
Recursion (RXRX) reported its Q3 2021 results, highlighting progress in drug discovery through its Recursion Map and an expanding clinical portfolio. The company is preparing to initiate Phase 2 and Phase 2/3 studies for four clinical programs in early 2022. Financially, Recursion ended Q3 with $578.9 million in cash and reported $2.5 million in revenue, up from $1.0 million in Q3 2020. However, R&D expenses rose to $33.2 million and general administrative costs increased to $15.7 million, leading to a net loss of $47.4 million, compared to $23.9 million a year prior.
Recursion (NASDAQ: RXRX) announced FDA Fast Track designation for REC-2282, an oral small molecule HDAC inhibitor targeting NF2-mutated meningiomas. This designation accelerates drug review for unmet medical needs. REC-2282 aims to benefit neurofibromatosis type-2 patients, with enrollment in a Phase 2/3 study expected to start early next year. Over 34,000 sporadic meningiomas are diagnosed annually in the U.S., with a significant portion driven by NF2 mutations, highlighting an urgent medical need for effective therapies.
BioHive has appointed Katelin Roberts as its full-time Executive Director, effective immediately, after serving in an interim capacity since its launch. BioHive aims to enhance Utah's growing life sciences industry. Roberts, previously CEO of Line Logic, brings extensive leadership experience. BioHive comprises over 1,100 companies in Utah's life sciences sector, employing over 130,000 individuals. The organization focuses on innovation and collaboration to strengthen the state's economy and improve patient outcomes.
Recursion (NASDAQ: RXRX) has received orphan drug designation from the U.S. FDA for its drug REC-4881, aimed at treating familial adenomatous polyposis (FAP). This designation supports the development of therapies for rare conditions and provides incentives such as tax credits and potential market exclusivity. REC-4881 is a small molecule MEK1/2 inhibitor intended to reduce tumor size in FAP patients, for whom no approved therapies currently exist. With approximately 50,000 cases in the US and Europe, the company plans a Phase 2 clinical trial to assess REC-4881's safety and efficacy within the next year.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology firm, announced its Q2 2021 financial results, reporting $2.5 million in revenue, up from $186,000 in Q2 2020, aided by collaboration with Bayer. The company has a robust pipeline with 48 active R&D programs, including 4 clinical and 4 preclinical programs. Key developments include plans for several Phase 2 trials and the advancement of its first internally developed new chemical entity towards IND-enabling studies. Recursion also aims to expand operations to Canada and enhance capabilities through partnerships and a newly formed Therapeutics Advisory Board.